|
SE504828C2
(sv)
|
1990-04-11 |
1997-05-12 |
Sandvik Ab |
Hammaranordning där kolv och borrkrona har omvänd design relativt varandra vad gäller impedans
|
|
TWI309240B
(en)
|
2004-09-17 |
2009-05-01 |
Hoffmann La Roche |
Anti-ox40l antibodies
|
|
JP5238936B2
(ja)
|
2005-03-25 |
2013-07-17 |
ジーアイティーアール,インク. |
Gitr結合分子およびその使用
|
|
DK1879573T3
(da)
|
2005-05-10 |
2013-02-25 |
Incyte Corp |
Modulatorer af indolamin 2,3-dioxygenase og fremgangsmåder til anvendelse deraf
|
|
KR101704734B1
(ko)
|
2005-07-01 |
2017-02-09 |
이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. |
예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
|
|
ES2540561T3
(es)
|
2005-12-20 |
2015-07-10 |
Incyte Corporation |
N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa
|
|
US7696166B2
(en)
|
2006-03-28 |
2010-04-13 |
Albany Molecular Research, Inc. |
Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
|
|
CA2663057C
(en)
|
2006-09-19 |
2015-12-08 |
Incyte Corporation |
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
|
|
CL2007002650A1
(es)
|
2006-09-19 |
2008-02-08 |
Incyte Corp |
Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
|
|
EP1987839A1
(en)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
|
PT2175884T
(pt)
|
2007-07-12 |
2016-09-21 |
Gitr Inc |
Terapias de combinação empregando moléculas de ligação a gitr
|
|
EP2044949A1
(en)
|
2007-10-05 |
2009-04-08 |
Immutep |
Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
|
|
WO2009073620A2
(en)
|
2007-11-30 |
2009-06-11 |
Newlink Genetics |
Ido inhibitors
|
|
AU2008343932B2
(en)
*
|
2007-12-19 |
2013-08-15 |
Amgen Inc. |
Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
MX356367B
(es)
|
2008-12-09 |
2018-05-25 |
Genentech Inc |
Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
|
|
CN102257076B
(zh)
|
2008-12-18 |
2014-07-30 |
纳幕尔杜邦公司 |
具有新颜料的粉末涂料组合物
|
|
IN2015DN02826A
(cg-RX-API-DMAC10.html)
|
2009-09-03 |
2015-09-11 |
Merck Sharp & Dohme |
|
|
EP2493862B1
(en)
|
2009-10-28 |
2016-10-05 |
Newlink Genetics Corporation |
Imidazole derivatives as ido inhibitors
|
|
DK2510010T3
(en)
|
2009-12-10 |
2015-12-14 |
Hoffmann La Roche |
Antibodies that bind to human CSF1R extracellular domain 4 and their use
|
|
DK2542256T3
(da)
|
2010-03-04 |
2019-08-26 |
Macrogenics Inc |
Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
|
|
RU2617971C2
(ru)
|
2010-03-05 |
2017-04-28 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против csf-1r человека и их применение
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
EP3943154A1
(en)
|
2010-05-04 |
2022-01-26 |
Five Prime Therapeutics, Inc. |
Antibodies that bind csf1r
|
|
NZ729044A
(en)
|
2010-09-09 |
2020-07-31 |
Pfizer |
4-1bb binding molecules
|
|
US8580399B2
(en)
|
2011-04-08 |
2013-11-12 |
Universal Display Corporation |
Substituted oligoazacarbazoles for light emitting diodes
|
|
NO2694640T3
(cg-RX-API-DMAC10.html)
|
2011-04-15 |
2018-03-17 |
|
|
|
CA2833636A1
(en)
|
2011-04-20 |
2012-10-26 |
Amplimmune, Inc. |
Antibodies and other molecules that bind b7-h1 and pd-1
|
|
KR20140068883A
(ko)
|
2011-09-28 |
2014-06-09 |
이데미쓰 고산 가부시키가이샤 |
유기 전계 발광 소자용 재료 및 이를 사용한 유기 전계 발광 소자
|
|
BR112014012819B1
(pt)
|
2011-11-28 |
2022-08-16 |
Merck Patent Gmbh |
Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
|
|
MX356337B
(es)
|
2011-12-15 |
2018-05-23 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
|
MX2014008961A
(es)
|
2012-02-06 |
2014-10-14 |
Genentech Inc |
Composiciones y metodos para utilizar inhibidores de csf1r.
|
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
KR20150018533A
(ko)
|
2012-05-11 |
2015-02-23 |
파이브 프라임 테라퓨틱스, 인크. |
콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
|
|
AR091649A1
(es)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
|
|
CN107759690A
(zh)
|
2012-08-31 |
2018-03-06 |
戊瑞治疗有限公司 |
用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
|
|
UA115576C2
(uk)
|
2012-12-06 |
2017-11-27 |
Байєр Фарма Акцієнгезелльшафт |
Похідні бензимідазолу як антагоністи ер4
|
|
EP2961747B1
(en)
|
2013-02-27 |
2017-11-15 |
Bristol-Myers Squibb Company |
Carbazole compounds useful as bromodomain inhibitors
|
|
US9492460B2
(en)
|
2013-02-27 |
2016-11-15 |
Bristol-Myers Squibb Company |
Carbazole compounds useful as bromodomain inhibitors
|
|
EP2970312B1
(en)
|
2013-03-11 |
2017-11-15 |
The Regents of The University of Michigan |
Bet bromodomain inhibitors and therapeutic methods using the same
|
|
EA201990240A1
(ru)
|
2013-12-24 |
2019-06-28 |
Бристол-Маерс Сквибб Компани |
Новые трициклические соединения в качестве противораковых средств
|
|
US9458156B2
(en)
|
2014-12-23 |
2016-10-04 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
|
US10662193B2
(en)
|
2014-01-21 |
2020-05-26 |
Ac Immune Sa |
Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
|
|
US9580430B2
(en)
|
2014-02-28 |
2017-02-28 |
The Regents Of The University Of Michigan |
9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
|